爪周囲炎治療市場の2030年までの予測：製品、タイプ、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界の爪周囲炎治療市場は2023年に5億734万米ドルを占め、予測期間中にCAGR 9.2％で成長し、2030年には9億3,942万米ドルに達すると予測されています。

爪周囲炎は一般的な爪の感染症で、指の爪や足の爪の周囲の皮膚の炎症が特徴です。これは細菌、真菌、またはその両方によって引き起こされ、発赤、腫脹、疼痛を引き起こします。治療には、温浴、適切な創部ドレナージ、細菌感染には抗生物質の外用または内服、真菌感染には抗真菌薬の内服が必要で、重症例や再発例では外科的治療が必要になることもあります。

糖尿病患者の増加

糖尿病患者は、免疫システムの低下、神経損傷、血液循環の低下により、爪甲真菌症などの爪感染症にかかりやすく、細菌や真菌による爪感染症にかかりやすいです。世界の糖尿病罹患率の上昇に伴い、爪疾患を含む糖尿病関連合併症の発生率も増加しています。糖尿病患者はしばしば感染症の管理に課題を抱えており、爪周囲炎に対する迅速かつ効果的な治療が必要とされています。

偽造薬

偽造薬や未規制薬は深刻な脅威であり、パロニーキアの治療法を求めている人々に、効果のない、標準以下の、あるいは有害な治療法を提供する可能性があります。このような未承認医薬品は、品質管理、適切な有効性、安全性の基準を欠いているため、ヘルスケアの専門家や患者の間で、治療の信頼性や潜在的な副作用に対する懸念が高まっています。こうした非正規品の存在は、市場が提供する医薬品に対する信頼を損ない、市場の成長を阻害しています。

技術の進歩

革新的技術により、製剤の改良、ドラッグデリバリーの標的化、診断ツールの強化が可能になります。ナノテクノロジー、経皮パッチ、高度な画像検査や分子検査は、より効果的で正確な治療アプローチを可能にします。さらに、遠隔医療は遠隔診療を容易にし、専門医療へのアクセスを拡大します。このような技術的進歩は、治療の有効性、患者の経験、パロニーキア治療の全体的な状況を向上させ、市場における技術革新と成長の機会を促進しています。

限られた認知度

パロニーキア、その症状、適時医療を受けることの重要性についての知識が十分でないため、診断や治療が遅れる可能性があります。予防策や利用可能な治療オプションに関する認識が乏しいため、早期介入が妨げられ、爪の感染症の進行につながる可能性があります。このような限られた意識は、患者数を減少させ、効果的な爪周囲炎治療の採用を妨げることによって、市場の成長に影響を与えます。

COVID-19の影響

致命的なコロナウイルスは瞬く間に世界中に広がり、病院を圧倒し、リソースを振り向け、必要のない医療サービスへのアクセスを制限しました。このため、ヘルスケアシステムに大きな混乱が生じ、パロニーキアの診断、治療、管理に影響が出ただけでなく、ヘルスケアサービスへのアクセスも遅れたり、低下したりしました。感染症や、痛みや炎症などの悪影響を経験している人々が問題を解決するためには、サービスの再開を待たなければならないです。

予測期間中、慢性爪周囲炎セグメントが最大となる見込み

慢性パロニーキア・セグメントが最大のシェアを占めると推定されます。慢性爪周囲炎は、多くの場合、真菌や細菌感染、刺激物、または反復性外傷や基礎疾患などの素因によって生じる長期的な症状です。慢性爪周囲炎の治療には、抗真菌薬や抗生物質の外用薬、経口療法、温浴、潜在的な刺激に対処する予防策が含まれます。また、慢性爪周囲炎は再発を繰り返すため、長期にわたる専門的な治療が必要となります。そのため、この種の病気の治療に特化した市場が存在します。

ゲンタマイシン軟膏は予測期間中に最も高いCAGRが見込まれる

ゲンタマイシン軟膏セグメントは、予測期間中に有利な成長を遂げると予測されています。ゲンタマイシン軟膏にはゲンタマイシンが含まれており、広範囲の細菌に有効な抗生物質です。爪の患部に直接塗布することで、ゲンタマイシン軟膏は細菌感染をターゲットとし、炎症を抑えて治癒を促進します。さらに、局所的な塗布と抗菌特性により、軽度から中等度の細菌性爪周囲炎に対する貴重な治療オプションとなります。この分野は、特に標的を絞った抗菌療法を必要とする患者を対象としており、爪周囲炎などの細菌性爪感染症に対処するための局所治療薬の市場拡大に貢献しています。

最大のシェアを占める地域

アジア太平洋地域は、ヘルスケアに対する意識の高まり、爪感染症の有病率の上昇、医療インフラの改善により、推定期間中に最大の市場シェアを占めました。この地域の多様な人口とライフスタイルの変化が、爪周囲炎の発生率の増加に寄与しています。さらに、パロニーキアを患う人口が増加し、この問題の治療に対する支出が増加していること、医療インフラの改善と爪感染症に関する認知の促進を目的とした好意的な政府イニシアチブの普及が急増していることが、市場成長の需要を後押ししています。

CAGRが最も高い地域：

北米は、老人人口の急増、実行可能な治療法に関する人々の知識の増加、米国やカナダなどの国々における大手市場プレイヤーの強固な存在感により、予測期間中に収益性の高い成長を示すことが期待されます。さらに、新しい局所療法、抗真菌薬、抗生物質などの最先端のパロニーキア治療法の迅速な開拓は、クリニックや病院で提供される治療法の多様性を増大させ、市場にプラスの影響を与えそうです。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の爪囲炎治療市場：製品別

• ムピロシン軟膏
• ゲンタマイシン軟膏
• フシジン酸軟膏
• ジクロキサシリン
• その他の製品

第6章 世界の爪囲炎治療市場：タイプ別

• 慢性爪囲炎
• 急性爪囲炎
• 化膿性爪囲炎
• カンジダ性爪囲炎
• その他のタイプ

第7章 世界の爪囲炎治療市場：エンドユーザー別

• 皮膚科センター
• 病院とクリニック
• その他のエンドユーザー

第8章 世界の爪囲炎治療市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第9章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Glenmark Generics Ltd
• Eli Lilly Company
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd
• Jonakayem Pharma Formulation
• Fougera Pharmaceuticals Inc
• Allergen Plc
• Johnson & Johnson Services Inc.
• Bayer AG
• Merck & Co. Inc.
• Perrigo New York Inc.
• Novartis AG
• Pfizer Inc.
• Taro Pharmaceutical Industries
• Sandoz International GmbH

List of Tables

• Table 1 Global Paronychia Treatment Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 3 Global Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 4 Global Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 5 Global Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 6 Global Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 7 Global Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 8 Global Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 9 Global Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 10 Global Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 11 Global Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 12 Global Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 13 Global Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 14 Global Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 15 Global Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 16 Global Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 17 Global Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 18 North America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 19 North America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 20 North America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 21 North America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 22 North America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 23 North America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 24 North America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 25 North America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 26 North America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 27 North America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 28 North America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 29 North America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 30 North America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 31 North America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 32 North America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 33 North America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 34 North America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 35 Europe Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 36 Europe Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 37 Europe Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 38 Europe Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 39 Europe Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 40 Europe Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 41 Europe Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 42 Europe Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 43 Europe Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 44 Europe Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 45 Europe Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 46 Europe Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 47 Europe Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 48 Europe Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 49 Europe Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 50 Europe Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 51 Europe Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 52 Asia Pacific Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 53 Asia Pacific Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 54 Asia Pacific Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 55 Asia Pacific Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 56 Asia Pacific Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 57 Asia Pacific Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 58 Asia Pacific Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 59 Asia Pacific Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 60 Asia Pacific Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 61 Asia Pacific Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 62 Asia Pacific Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 63 Asia Pacific Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 64 Asia Pacific Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 65 Asia Pacific Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 66 Asia Pacific Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 67 Asia Pacific Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 68 Asia Pacific Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 69 South America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 70 South America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 71 South America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 72 South America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 73 South America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 74 South America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 75 South America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 76 South America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 77 South America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 78 South America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 79 South America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 80 South America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 81 South America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 82 South America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 83 South America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 84 South America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 85 South America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 86 Middle East & Africa Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
• Table 87 Middle East & Africa Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
• Table 88 Middle East & Africa Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
• Table 89 Middle East & Africa Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
• Table 90 Middle East & Africa Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
• Table 91 Middle East & Africa Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
• Table 92 Middle East & Africa Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
• Table 93 Middle East & Africa Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
• Table 94 Middle East & Africa Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
• Table 95 Middle East & Africa Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
• Table 96 Middle East & Africa Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
• Table 97 Middle East & Africa Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
• Table 98 Middle East & Africa Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
• Table 99 Middle East & Africa Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
• Table 100 Middle East & Africa Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
• Table 101 Middle East & Africa Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 102 Middle East & Africa Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Paronychia Treatment Market is accounted for $507.34 million in 2023 and is expected to reach $939.42 million by 2030 growing at a CAGR of 9.2% during the forecast period. Paronychia is a common nail infection characterized by inflammation of the skin surrounding the fingernail or toenail. This is caused by bacteria, fungi, or both, leading to redness, swelling, and pain. Treatment involves warm soaks, proper wound drainage, topical or oral antibiotics for bacterial infections, antifungal medications for fungal cases, and in severe or recurrent instances, surgical intervention may be necessary.

Market Dynamics:

Driver:

Significant rise in diabetes patients

Diabetic individuals are more susceptible to nail infections like paronychia due to compromised immune systems, nerve damage, and reduced blood circulation, making them susceptible to bacterial or fungal nail infections. With the escalating, global diabetes prevalence, there's been a corresponding increase in the incidence of diabetic-related complications, including nail disorders. Diabetic patients often experience challenges in managing infections, necessitating prompt and effective treatment for paronychia.

Restraint:

Counterfeit medications

Counterfeit or unregulated medications pose a serious threat, potentially offering ineffective, substandard, or even harmful treatments to individuals seeking remedies for paronychia. Such unauthorized drugs lack quality control, proper efficacy, and safety standards, raising concerns among healthcare professionals and patients about treatment reliability and potential adverse effects. The presence of these illegitimate products undermines trust in the market's offerings, hindering the market's growth.

Opportunity:

Advancements in technology

Innovative technologies offer improved drug formulations, targeted delivery systems, and enhanced diagnostic tools. Nanotechnology, transdermal patches, and sophisticated imaging or molecular testing enable more effective and precise treatment approaches. Additionally, telemedicine facilitates remote consultations, expanding access to specialized care. These technological advancements enhance treatment efficacy, patient experience, and the overall landscape of paronychia treatments, fostering opportunities for innovation and growth within the market.

Threat:

Limited awareness

Insufficient knowledge among individuals about paronychia, its symptoms, and the importance of seeking timely medical care may result in delayed diagnosis and treatment. Lack of awareness about preventive measures and available treatment options could hinder early intervention, leading to the progression of nail infections. This limited awareness impacts market growth by reducing the patient pool and impeding the adoption of effective paronychia treatments.

COVID-19 Impact

The deadly corona virus spread quickly around the world, overwhelming hospitals, redirecting resources, and restricting access to non-essential medical services. This caused major disruptions in healthcare systems that impacted paronychia diagnosis, treatment, and management, as well as delayed or decreased access to healthcare services. In order to get their problems resolved those who are experiencing infections and adverse consequences, including pain and inflammation, must wait for the services to resume.

The chronic paronychia segment is expected to be the largest during the forecast period

The chronic paronychia segment is estimated to hold the largest share. Chronic paronychia is a long-term condition that often arises from fungal or bacterial infections, irritants, or predisposing factors such as repetitive trauma or underlying health conditions. Treatments for chronic paronychia include topical antifungal or antibiotic medications, oral therapies, warm soaks, and preventive measures addressing potential irritants. Moreover, chronic paronychia requires long-term, specialised therapy due to its recurrent nature. As a result, there is a dedicated market focus on treating this type of illness.

The gentamicin ointment segment is expected to have the highest CAGR during the forecast period

The gentamicin ointment segment is anticipated to have lucrative growth during the forecast period. Gentamicin ointment contains gentamicin, an antibiotic effective against a wide range of bacteria. Applied directly to the affected nail area, gentamicin ointment targets bacterial infections, reducing inflammation and promoting healing. Furthermore, its localised application and antibacterial properties make it a valuable treatment option for mild-to-moderate bacterial paronychia cases. This segment caters specifically to individuals requiring targeted antimicrobial therapy, contributing to the market's array of topical treatments for addressing bacterial nail infections like paronychia.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to increasing healthcare awareness, a rising prevalence of nail infections, and improving healthcare infrastructure. The region's diverse population and changing lifestyles contribute to the growing incidence of paronychia. Moreover, due to the increased population base suffering from paronychia and their rising spending on the treatment of this issue, and the surging prevalence of favourable government initiatives aimed at improving healthcare infrastructure and promoting awareness about nail infections, this is driving the demand for market growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to a surge in the geriatric population, growing people's knowledge of viable treatments, and the robust presence of major market players in countries like the US and Canada. Moreover, the quick development of cutting-edge paronychia treatment alternatives, such as new topical therapies, antifungal medications, and antibiotics, which have increased the variety of treatment methods offered in clinics and hospitals, is likely to impact the market positively.

Key players in the market:

Some of the key players in the Paronychia Treatment Market include Glenmark Generics Ltd, Eli Lilly Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Jonakayem Pharma Formulation, Fougera Pharmaceuticals Inc, Allergen Plc, Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., Perrigo New York Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries and Sandoz International GmbH.

Key Developments:

In January 2023, The National Medical Products Administration of China announced that they have approved the mobocertinib for treatment of the adult patients with advanced and metastatic non-small lung cancer. The newly developed treatment technique was mostly experienced with mobocertinib including paronychia, diarrhoea, rash, and decreased appetite.

Products Covered:

• Mupirocin Ointment
• Gentamicin Ointment
• Fusidic Acid Ointment
• Dicloxacillin
• Other Products

Types Covered:

• Chronic Paronychia
• Acute Paronychia
• Pyogenic Paronychia
• Candidal Paronychia
• Other Types

End Users Covered:

• Dermatology Centers
• Hospitals & Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Paronychia Treatment Market, By Product

• 5.1 Introduction
• 5.2 Mupirocin Ointment
• 5.3 Gentamicin Ointment
• 5.4 Fusidic Acid Ointment
• 5.5 Dicloxacillin
• 5.6 Other Products

6 Global Paronychia Treatment Market, By Type

• 6.1 Introduction
• 6.2 Chronic Paronychia
• 6.3 Acute Paronychia
• 6.4 Pyogenic Paronychia
• 6.5 Candidal Paronychia
• 6.6 Other Types

7 Global Paronychia Treatment Market, By End User

• 7.1 Introduction
• 7.2 Dermatology Centers
• 7.3 Hospitals & Clinics
• 7.4 Other End Users

8 Global Paronychia Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Glenmark Generics Ltd
• 10.2 Eli Lilly Company
• 10.3 GlaxoSmithKline plc
• 10.4 Teva Pharmaceutical Industries Ltd
• 10.5 Jonakayem Pharma Formulation
• 10.6 Fougera Pharmaceuticals Inc
• 10.7 Allergen Plc
• 10.8 Johnson & Johnson Services Inc.
• 10.9 Bayer AG
• 10.10 Merck & Co. Inc.
• 10.11 Perrigo New York Inc.
• 10.12 Novartis AG
• 10.13 Pfizer Inc.
• 10.14 Taro Pharmaceutical Industries
• 10.15 Sandoz International GmbH